61 related articles for article (PubMed ID: 3723990)
1. [The pharmacokinetics of doxorubicin].
Erttmann R; Grandt M; Erb N; Garbrecht M; Landbeck G
Klin Padiatr; 1986; 198(3):271-6. PubMed ID: 3723990
[TBL] [Abstract][Full Text] [Related]
2. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin.
Schwartz GK; Ward D; Saltz L; Casper ES; Spiess T; Mullen E; Woodworth J; Venuti R; Zervos P; Storniolo AM; Kelsen DP
Clin Cancer Res; 1997 Apr; 3(4):537-43. PubMed ID: 9815717
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of non-renal elimination mechanisms of methotrexate (MTX)].
Erttmann R; Gkanatsas A
Monatsschr Kinderheilkd; 1985 Aug; 133(8):516-9. PubMed ID: 3876505
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
[TBL] [Abstract][Full Text] [Related]
8. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
9. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin.
Wurz GT; Soc L; Emshoff VD; Cadman TB; DeGregorio MW
Cancer Chemother Pharmacol; 1998; 42(5):363-6. PubMed ID: 9771949
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours.
Thomson AH; Vasey PA; Murray LS; Cassidy J; Fraier D; Frigerio E; Twelves C
Br J Cancer; 1999 Sep; 81(1):99-107. PubMed ID: 10487619
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of cremophor EL with bolus doxorubicin.
Millward MJ; Webster LK; Rischin D; Stokes KH; Toner GC; Bishop JF; Olver IN; Linahan BM; Linsenmeyer ME; Woodcock DM
Clin Cancer Res; 1998 Oct; 4(10):2321-9. PubMed ID: 9796961
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient.
Ritzmo C; Söderhäll S; Karlén J; Nygren H; Eksborg S
Pediatr Hematol Oncol; 2007 Sep; 24(6):437-45. PubMed ID: 17710661
[TBL] [Abstract][Full Text] [Related]
20. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
Holmes FA
Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]